microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review).
Lung cancer remains the leading cause of cancer-related death worldwide             for both men and women, and non-small cell lung cancer (NSCLC) accounts for approximately             80% of all cases. Despite improvements in early diagnosis and newly developed             therapies, the 5-year survival rate for NSCLC patients remains low (15%). Therapy             in NSCLC has reached a plateau. Understanding genomic medicine may provide insight             into the oncogenesis of lung cancer and open the door to molecular diagnosis,             new biomarkers and a more accurate prognosis of lung cancer. It is well known             that almost half of the genes regulated by microRNAs (miRNAs) are located in cancer-associated             genomic regions. In the present study, we discuss the potential of miRNAs to function             as suppressors and biomarkers for chemoresistance and prognosis of lung cancer.
Department of Respiratory Desease, The General Hospital of the Chinese People's Liberation Army, Beijing 100853, PR China.
Yan-Wen
YW
Jiang
Liang-An
LA
Chen
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D035683:MicroRNAs / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D009857:Oncogenes / Q000187:drug effects*
D000970:Antineoplastic Agents; D015415:Biomarkers; D035683:MicroRNAs; D066246:ErbB Receptors